Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
申请人:NSAB, Filial af NeuroSearch Sweden AB, Sverige
公开号:US08188301B2
公开(公告)日:2012-05-29
The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1-pyrrolidinols for the treatment of central nervous system disorders.
NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION
申请人:NSAB, Filial af NeuroSearch Sweden AB, Sverige
公开号:EP2155671A2
公开(公告)日:2010-02-24
US8188301B2
申请人:——
公开号:US8188301B2
公开(公告)日:2012-05-29
[EN] NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION<br/>[FR] NOUVELLES PHÉNYLPYRROLIDINES DISUBSTITUÉES EN TANT QUE MODULATEURS DE LA NEUROTRANSMISSION CATÉCHOLAMINERGIQUE CORTICALE
申请人:NSAB OF NEUROSEARCH SWEDEN AB
公开号:WO2008148801A2
公开(公告)日:2008-12-11
(EN) The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1 - pyrrolidinols for the treatment of central nervous system disorders.(FR) La présente invention porte sur l'utilisation de composés qui augmentent les taux extracellulaires de catécholamines, de dopamine et de norépinéphrine, dans des zones corticales cérébrales du cerveau mammifère, et plus spécifiquement sur l'utilisation de 3-phényl disubstitué -1 - pyrrolidinols pour le traitement de troubles du système nerveux central.
DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION
申请人:Sonesson Clas
公开号:US20100179211A1
公开(公告)日:2010-07-15
The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1-pyrrolidinols for the treatment of central nervous system disorders.